Bifogade filer
Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Paxman, the global leader in cancer side effect management, today announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT® codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet.
Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: https://www.ama-assn.org/system/files/feb-2026-summary-of-panel-actions.pdf
The three-code structure mirrors the established coding framework for Paxman’s FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement.
During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN — a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients’ quality of life.
In October, The Paxman Neuropathy System was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA.
Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027.
Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN.
Richard Paxman, Chief Executive Officer of Paxman, commented:
“The award of Category III CPT codes represents an important and encouraging step for cryocompression therapy in the United States and establishes a formal coding and reporting pathway as we introduce this innovative preventative therapy to the U. S. market. Our experience with scalp cooling has demonstrated the value of clear coding, structured data collection, and early payer engagement. Entering the market with an established Category III code places Paxman in a strong position from the outset. Our expansion into cryocompression to reduce CIPN reflects Paxman’s long-term commitment to advancing side effect management in oncology. With robust clinical programs underway, we are building the evidence required to support thoughtful integration of this therapy into routine oncology care.”
CIPN is a severe dose-limiting toxicity impacting the quality of life for over 3 million cancer patients globally every year.1, 2 Approximately 40 percent of patients on taxane or platinum-based chemotherapy agents experience painful symptoms that may persist for months or longer.3 CIPN frequently results in chemotherapy dose reductions or delays, potentially limiting optimal treatment delivery. For many patients, symptoms can impair daily functions, affecting mobility, dexterity, and overall quality of life. CIPN increases healthcare costs by approximately $17,000 per patient, with lost workdays for the patient of >50 days. 4, 5
As cancer survival improves and use of neurotoxic agents remains widespread, the clinical and economic burden of CIPN represents an increasing area of focus within oncology care and side effect management.
- Seretny, M., G. L. Currie, E. S. Sena, S. Ramnarine, R. Grant, M. R. MacLeod, L. A. Colvin, and M. Fallon. 2014. "Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis." Pain 155 (12):2461-70. doi: 10.1016/j.pain.2014.09.020.
- 2. Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019 Jun;20(6):769-780. doi: 10.1016/S1470-2045(19)30163-9. Epub 2019 May 8. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346. doi: 10.1016/S1470-2045(19)30375-4. PMID: 31078462.
- 3. D'Souza RS, Saini C, Hussain N, et al Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000–24Regional Anesthesia & Pain Medicine Published Online First: 29 January 2025. doi: 10.1136/rapm-2024-106229
- Pike, C. T., H. G. Birnbaum, C. E. Muehlenbein, G. M. Pohl, and R. B. Natale. 2012a. "Healthcare costs and workloss burden of patients with chemotherapy associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer." Chemother Res Pract 2012:913848. doi: 10.1155/2012/913848 .
- Molassiotis, Alex, Hui Lin Cheng, Violeta Lopez, Joseph SK Au, Alexandre Chan, Aishwarya Bandla, KT Leung, YC Li, KH Wong, and Lorna KP Suen. 2019. "Are we mis-estimating chemotherapy- induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy." BMC cancer 19 (1):132.